Article info
Letter
Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients
- Correspondence to Professor Caifeng Li, Department of Rheumatology, Beijing Children's Hospital, Capital Medical University, National Centre for Children’s Health, Beijing, 100045, China; caifeng_li{at}yeah.net
Citation
Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients
Publication history
- Received January 19, 2023
- Accepted May 15, 2023
- First published June 6, 2023.
Online issue publication
November 01, 2023
Article Versions
- Previous version (18 October 2023).
- You are viewing the most recent version of this article.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.